Authors

• Joan Carles (ORCID: https://orcid.org/0000-0002-9983-5934)
• Karim S. Fizazi (ORCID: https://orcid.org/0000-0002-6068-9474)
• Nobuaki Matsubara (ORCID: https://orcid.org/0000-0002-9203-4245)
• Curtis Dunshee (ORCID: https://orcid.org/0000-0002-3088-8309)
• Michael A. Zielinski
• Stefanie Zschäbitz (ORCID: https://orcid.org/0000-0001-8917-3263)
• Jae Young Joung (ORCID: https://orcid.org/0000-0002-7971-211X)
• Robert J. Jones (ORCID: https://orcid.org/0000-0002-2904-6980)
• Fred Saad (ORCID: https://orcid.org/0000-0003-2986-5617)
• Peter C.C. Fong (ORCID: https://orcid.org/0000-0003-2689-8958)
• Ugo De Giorgi (ORCID: https://orcid.org/0000-0001-7520-2908)
• Arun Azad (ORCID: https://orcid.org/0000-0001-7350-5622)
• Nicola Di Santo (ORCID: https://orcid.org/0000-0001-7210-734X)
• André P. Fay (ORCID: https://orcid.org/0000-0002-8588-7012)
• Liza DeAnnuntis (ORCID: https://orcid.org/0000-0002-7974-2343)
• Neal D. Shore (ORCID: https://orcid.org/0000-0001-5767-0548)
• Neeraj Agarwal (ORCID: https://orcid.org/0000-0002-1025-4114)
• Jan Oldenburg (ORCID: https://orcid.org/0000-0002-4454-905X)
• Xun Lin (ORCID: https://orcid.org/0000-0001-9882-0223)

Institutions

• University of Auckland (NZ)
• Pfizer (United States) (US)
• University of Utah (US)
• Heidelberg University (DE)
• Université Paris-Saclay (FR)
• Akershus University Hospital (NO)
• Beatson West of Scotland Cancer Centre (GB)
• Peter MacCallum Cancer Centre (AU)
• Huntsman Cancer Institute (US)
• Auckland City Hospital (NZ)
• Institut Gustave Roussy (FR)
• University Hospital Heidelberg (DE)
• Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IT)
• National Center for Tumor Diseases (DE)
• National Cancer Center (KR)
• Arizona Pain Specialists (US)
• Vall d'Hebron Hospital Universitari (ES)
• Centre Hospitalier de l’Université de Montréal (CA)
• National Cancer Center Hospital East (JP)
• Istituti di Ricovero e Cura a Carattere Scientifico (IT)
• Carolina Urologic Research Center (US)
• Vall d'Hebron Institute of Oncology (ES)
• Pontifícia Universidade Católica do Rio Grande do Sul (BR)
• University of Glasgow (GB)

Publication Details

Journal

European Journal of Cancer

Published

2024-10-19

DOI

https://doi.org/10.1016/j.ejca.2024.115078

Citations

10

Primary Topic

PARP inhibition in cancer therapy

Type

article

Field-Weighted Citation Impact

2.83

Funders

• Amgen
• Bristol-Myers Squibb
• Eli Lilly and Company
• Pfizer
• AstraZeneca
• GlaxoSmithKline
• Sanofi
• Gilead Sciences
• Boston Scientific Corporation
• Merck KGaA
• Exelixis
• Clovis Oncology
• Myriad Genetics
• Incyte
• Advanced Accelerator Applications
• UroGen Pharma
• MacroGenics
• Seagen
• Invitae
• Eisai
• Astellas Pharma
• Ipsen
• Australian and New Zealand Urogenital and Prostate Cancer Trials Group
• Genentech
• Chugai Pharmaceutical
• Foundation Medicine
• Daiichi Sankyo Europe
• Cilag